secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2023-08-11T23:59:59+00:00
Accession:  0001193125-23-209833
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Disc Medicine Q2 net loss $15.9M, cash $378M; BEACON bitopertin data positive
-----------------------------------------------------------------------------

- Net loss $15.9M in Q2 2023 vs $9.6M in Q2 2022; R&D expense $12.1M, G&A $5.2M.
- Cash and equivalents $377.6M as of June 30, 2023; expected to fund operations into 2026.
- BEACON Phase 2 bitopertin data showed dose-dependent PPIX reduction, improved sunlight tolerance; well-tolerated.
- Enrolling two Phase 1b/2 studies for DISC-0974 (NDD-CKD and myelofibrosis); initial data expected year-end 2023.
- Completed upsized public offering in June 2023 for $157.8M gross proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000119312523209833/0001193125-23-209833-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000119312523209833/d471506d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-209833

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer